KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine

Chemotherapy

Volumn 57, Issue 1, 2011, Pages 12-16

  Taba, Kumiko ^a   Kuramitsu, Yasuhiro ^a   Ryozawa, Shomei ^a   Yoshida, Kanako ^a   Tanaka, Toshiyuki ^a   Mori Iwamoto, Sayaka ^a   Maehara, Shin Ichiro ^b   Maehara, Yoshihiko ^b   Sakaida, Isao ^a   Nakamura, Kazuyuki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Heat shock protein 27; KNK437; Liquid chromatography tandem mass spectrometry; Pancreatic cancer; Proteomics; Two dimensional gel electrophoresis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; GEMCITABINE; HEAT SHOCK PROTEIN 27; KNK 437; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; BENZHYDRYL COMPOUNDS; DEOXYCYTIDINE; DOWN-REGULATION; HSP27 HEAT-SHOCK PROTEINS; HUMANS; PANCREATIC NEOPLASMS; PYRROLIDINONES; TUMOR CELLS, CULTURED;

EID: 78649515098     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321019     Document Type: Article

References (26)

1. Williamson RC: Pancreatic cancer: the greatest oncological challenge. Br Med J (Clin Res Ed) 1988;13:445-446.
2. Gordis L, Gold EB: Epidemiology of pancreatic cancer. World J Surg 1984;8:808-821. (Pubitemid 15024902)
3. Tada M, Arizumi T, Nakai Y, Sasaki T, Kogure H, Togawa O, Matsubara S, Tsujino T, Hirano K, Sasahira N, Isayama H, Kawabe T, Omata M: Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy. Chemotherapy 2008;54:302-308.
4. Kim H, Park JH, Shin SJ, Kim MJ, Bang SJ, Park NH, Nah YW, Nam CW, Joo KR, Min YJ: Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study. Chemotherapy 2008;54:54-62. (Pubitemid 350308286)
5. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:1-5.
6. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuriya K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K, Sakaida I: Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 2007;31:1345-1350.
7. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K, Nakamura K, Sakaida I: A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Report 2008;1:429-434.
8. Mori-Iwamoto S, Taba K, Kuramitsu Y, Ryozawa S, Tanaka T, Maehara S, Maehara Y, Okita K, Nakamura K, Sakaida I: Interferon-γ down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Pancreas 2009;38:224-226.
9. Yokota S, Kitahara M, Nagata K: Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 2000;60:2942-2948. (Pubitemid 30395819)
10. Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K, Maehara Y: Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer 2004;112:184-189. (Pubitemid 39244357)
11. Tanaka T, Kuramitsu Y, Fujimoto M, Naito S, Oka M, Nakamura K: Down-regulation of two isoforms of ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) correlates with high metastatic potentials of human SN12C renal cell carcinoma cell clones. Electrophoresis 2008;29:2651-2659. (Pubitemid 351911893)
12. Kuramitsu Y, Harada T, Takashima M, Yokoyama Y, Hidaka I, Iizuka N, Toda T, Fujimoto M, Zhang X, Sakaida I, Okita K, Oka M, Nakamura K: Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues of patients infected with hepatitis C virus. Electrophoresis 2006;27:1651-1658.
13. Tamesa M, Kuramitsu Y, Fujimoto M, Maeda N, Nagashima Y, Tanaka T, Yamamoto S, Oka M, Nakamura K: Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 2009;30:2168-2181.
14. Kuramitsu Y, Miyamoto H, Tanaka T, Zhang X, Fujimoto M, Ueda K, Tanaka T, Hamano K, Nakamura K: Proteomic differential display analysis identified up-regulated astrocytic phsphoprotein PEA-15 in human malignant pleural mesothelioma cell lines. Proteomics 2009;9:5078-5089.
15. Koike T, Uno S, Ishizawa M, Takahashi H, Ikeda K, Yokota S, Makishima M: The heat shock protein inhibitor KNK437 induces neurite outgrowth in PC12 cells. Neurosci Lett 2006;410:212-217. (Pubitemid 44750348)
16. Manwell LA, Heikkila JJ: Examination of KNK437- and quercetin-mediated inhibition of heat shock-induced heat shock protein gene expression in Xenopus laevis cultured cells. Comp Biochem Physiol A Mol Integr Physiol 2007;148:521-530. (Pubitemid 47484224)
17. Voyer J, Heikkila JJ: Comparison of the effect of heat shock factor inhibitor, KNK437, on heat shock- and chemical stress-induced hsp30 gene expression in Xenopus laevis A6 cells. Comp Biochem Physiol A Mol Integr Physiol 2008;151:253-261.
18. Takahashi A, Yamakawa N, Mori E, Ohnishi K, Yokota S, Sugo N, Aratani Y, Koyama H, Ohnishi T: Development of thermotolerance requires interaction between polymerase-beta and heat shock proteins. Cancer Sci 2008;99:973-978. (Pubitemid 351997600)
19. Arrigo AP: Hsp27: novel regulator of intracellular redox state. IUBMB Life 2001;52:303-307.
20. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E: HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 1999;13:2061-2070. (Pubitemid 29517636)
21. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA: Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 1999;56:187-196. (Pubitemid 29494836)
22. Gibbons NB, Watson RW, Coffey RN, Brady HP, Fitzpatrick JM: Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 2000;45:58-65.
23. Urbani A, Poland J, Bernardini S, Bellincampi L, Biroccio A, Schnölzer M, Sinha P, Federici G: A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 2005;5:796-804. (Pubitemid 40316064)
24. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA: Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review. J Natl Cancer Inst 1993;85:1558-1570. (Pubitemid 23304684)
25. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-7105. (Pubitemid 32059190)
26. Romanucci M, Marinelli A, Sarli G, Della Salda L: Heat shock protein expression in canine malignant mammary tumours. BMC Cancer 2006;6:171.